Overview

LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy

Status:
Withdrawn
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, placebo-controlled, study testing whether LDX improves cognitive function and EF in 20 postmenopausal women who report onset of cognitive difficulties after oophorectomy (with or without subsequent chemo/adjunctive therapy). Brain imaging is included at critical time points to obtain objective data regarding effects of LDX as well as potential predictors of resilience in the face of oophorectomy.
Phase:
N/A
Details
Lead Sponsor:
University of Pennsylvania
Treatments:
Lisdexamfetamine Dimesylate